Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
Summary
Third Opinion Trial Synopsis:
We want to test if a new medicine mixture called ClaSPd safely and effectively helps people with multiple myeloma that has come back or didn't respond to other treatments. We think ClaSPd will work well because it contains a new medicine called Selinexor. We hope it will help more people with multiple myeloma.
We want to test if a new medicine mixture called ClaSPd safely and effectively helps people with multiple myeloma that has come back or didn't respond to other treatments. We think ClaSPd will work well because it contains a new medicine called Selinexor. We hope it will help more people with multiple myeloma.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: